Analysts think VRNA stock price could decrease by -3%
Jul 10, 2025, 11:25 AM
0.14%
What does VRNA do
Verona Pharma Plc develops therapeutics for respiratory diseases, focusing on its investigational inhaled drug, ensifentrine, for chronic obstructive pulmonary disease (COPD). Two additional formulations of ensifentrine are in Phase II development.
13 analysts think VRNA stock price will decrease by -2.63%. The current median analyst target is $102.00 compared to a current stock price of $104.75. The lowest analysts target is $75.75 and the highest analyst target is $121.80.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.